Form 4: Integrated Biopharma Director Damon DeSantis Granted 50,000 Stock Options

Integrated Biopharma Inc. Director Damon DeSantis was granted 50,000 stock options with an exercise price of $0.30, vesting in quarterly installments through June 2026.

Summary

• Damon DeSantis, a Director of Integrated Biopharma Inc. (INBP), was granted 50,000 stock options.
• The options have an exercise price of $0.30 per share.
• The grant date for these options was June 18, 2025.
• The options will vest in four equal installments of 12,500 shares each on September 30, 2025, December 31, 2025, March 31, 2026, and June 30, 2026.
• The options expire on June 18, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns management's interests with shareholders, generally viewed as a neutral to slightly positive event as it incentivizes long-term performance.

Positives

• The grant of 50,000 stock options to Director Damon DeSantis aligns his interests with shareholders, incentivizing long-term performance.
• The exercise price of $0.30 provides a clear target for stock appreciation.

Future Outlook

The vesting schedule for the stock options extends through June 2026, indicating a long-term incentive structure for the director, aligning his future performance with shareholder value.

Industry Context

This filing is a standard disclosure of insider compensation, common across all industries for publicly traded companies, and does not directly reflect broader industry trends in biopharma.

Related Party Transactions

• The grant of 50,000 stock options to Damon DeSantis, a Director of Integrated Biopharma Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can align management's interests with shareholders, potentially leading to improved long-term performance and shareholder value if the stock price increases above the exercise price.
• Management: Damon DeSantis receives additional incentive compensation, tying his financial interests more closely to the company's stock performance.

Next Steps

• First tranche of 12,500 stock options vests on September 30, 2025.
• Second tranche of 12,500 stock options vests on December 31, 2025.
• Third tranche of 12,500 stock options vests on March 31, 2026.
• Fourth and final tranche of 12,500 stock options vests on June 30, 2026.

Key Dates

Keywords

INBP, Integrated Biopharma, stock options, director compensation, beneficial ownership, SEC Form 4, Damon DeSantis